We have moved to new location, Please click on contact us  
Home  >  News
Eppen_MCX50_Dec2022
Pioma_Lactitol_3_Jan23.gif
you can get e-magazine links on WhatsApp. Click here
Biotechnology + Font Resize -

NKGen Biotech collaborates with Parkinson’s Foundation to bring its novel NK cell therapy to clinic for advanced Parkinson’s disease

Santa Ana, California
Monday, November 7, 2022, 16:00 Hrs  [IST]

NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell therapies, announced a collaboration with the Parkinson’s Foundation that will focus on ways to help accelerate NKGen’s clinical programme using its novel autologous NK cell therapy (SNK01) for the treatment of advanced Parkinson’s disease (PD) through its network of clinical partners and donors.

“Recent research has shown that NK cells can help remove alpha-synuclein proteins, reduce autoreactive T cell generated inflammation, and remove damaged neurons. We believe our non-genetically modified, enhanced, and expanded NK cells (SNK01) can provide an entirely new therapeutic approach to Parkinson’s disease which currently lacks effective disease modifying modalities,” said Paul Y. Song, MD, vice chairman of NKGen Biotech. “We are very impressed with the Parkinson’s Foundation’s holistic approach towards improving patient care and supporting cutting-edge research. We are confident that they will be a great partner for us as we bring our treatment for Parkinson’s disease to the clinic in 2023.”

“The Parkinson’s Foundation has a strong commitment to identify and accelerate promising scientific breakthroughs in the treatment of PD,” said John L. Lehr, president and CEO of the Parkinson’s Foundation. “We are looking to support novel innovative approaches in PD, and we are attracted to NKGen’s unwavering commitment to bring their NK cell therapy to the clinic very quickly.”

NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics.

The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
India Lab Expo
Pharma_Live_Expo_2023
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |